AI Articles and Analysis about Research and development

The clinical trial is a foundational pillar of the pharmaceutical drug discovery process. Essentially, clinical trials are research studies which seek to determine if a medical treatment or device is safe and effective for humans. While the pharmaceutical drug industry has experienced some fluctuations it remains a profitable market. Global prescription drug expenditures are estimated to reach nearly $1.5 trillion by 2021 according to Quintiles IMS Holding.  

One highly sought after engineering role at major tech companies today is the natural language processing, or NLP, engineer.

MicKinsey estimated that by 2030, up to 15% of cars sold will be autonomous vehicles. We detailed our own timeline for self-driving cars, pooling quotes and insights from executives at the top 11 global automakers.

Episode Summary: This week on AI in Industry, we speak with Amir Saffari, Senior Vice President of AI at BenevolentAI, a London-based pharmaceutical company that uses machine learning to find new uses for existing drugs and new treatments for diseases.

AI and machine learning software are beginning to integrate themselves as tools for efficiency and accuracy within pathology. According to a March 2018 digital pathology report produced by Allied Market Research, such software enables the “procurement, management and interpretation” of information and can be applied to multiple functions within the field of healthcare.

Artificial intelligence has already established a small but growing presence in the life sciences industry today, starting with drug discovery and development and now in emerging applications across the product life cycle.

Episode Summary: This episode explores the ways in which artificial intelligence has the potential to revolutionize the field of medicine. This week's guest, Turbine.ai's Dr. Kristóf Zsolt Szalay speaks to this topic, discussing research that hopes to create automated learning networks and algorithms designed to predict the development of human cells in response to drugs. This technological innovation would make it possible for near-instantaneous simulations to be run, allowing optimal combinations and optimal doses of drugs to be pinpointed and distributed to patients.

Episode summary: In this episode, we talk to Murali Aravamudan, Founder and CEO of AI-driven drug discovery startup Qrativ, a joint venture by the Mayo Clinic and biotech/data science firm nference. Murali and I discuss the surge of medical information and data in the medical industry, the role of artificial intelligence in developing drugs for treatments to various diseases, and the future of AI in drug discovery.